Juno, Celgene Report Impressive Results of CAR T-cell Therapy in B-cell Lymphoma
News
The CAR T-cell therapy JCAR017, developed by Juno Therapeutics and Celgene, eradicated B-cell lymphomas in more than two-thirds of patients with high-risk cancer, the companies announced. The response to the ... Read more